Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 5.09% |
| Q2 2025 | -38.63% |
| Q1 2025 | 1.69% |
| Q4 2024 | -38.28% |
| Q3 2024 | -8.22% |
| Q2 2024 | 0.96% |
| Q1 2024 | -12.30% |
| Q4 2023 | -12.92% |
| Q3 2023 | 14.00% |
| Q2 2023 | -3.19% |
| Q1 2023 | -20.37% |
| Q4 2022 | 14.43% |
| Q3 2022 | -12.58% |
| Q2 2022 | 24.27% |
| Q1 2022 | -3.90% |
| Q4 2021 | 14.98% |
| Q3 2021 | 5.76% |
| Q2 2021 | 14.64% |
| Q1 2021 | -15.92% |
| Q4 2020 | 35.86% |
| Q3 2020 | 15.29% |
| Q2 2020 | 0.47% |
| Q1 2020 | -81.48% |
| Q4 2019 | 217.26% |
| Q3 2019 | 39.18% |
| Q2 2019 | -13.40% |
| Q1 2019 | 32.98% |
| Q4 2018 | -33.22% |
| Q3 2018 | 1.28% |
| Q2 2018 | 17.26% |
| Q1 2018 | -21.73% |
| Q4 2017 | 14.71% |
| Q3 2017 | 0.60% |
| Q2 2017 | 11.34% |
| Q1 2017 | -19.14% |
| Q4 2016 | 9.01% |
| Q3 2016 | 3.44% |
| Q2 2016 | 15.76% |
| Q1 2016 | -11.81% |
| Q4 2015 | -8.87% |